
This post is sponsored by Sanofi & Regeneron
For some, it starts with a persistent cough that just won't go away.1 For others, it gets harder to catch their breath, even while walking up a flight of stairs or vacuuming the house.1, 2
There are many manifestations of chronic obstructive pulmonary disease (COPD)3 —a devastating respiratory condition that the World Health Organization (WHO) has declared the fourth leading cause of death worldwide1 —but often it takes years before patients are formally diagnosed.4
“Up to half of all people who are living with COPD don't even know they have the disease,” says Tonya Winders, president and CEO of the patient advocacy group Global Allergy & Airways Patient Platform (GAAPP).5,6

Up to half of all people who are living with COPD don't even know they have the disease.”
Tonya Winders, president and CEO of the patient advocacy group Global Allergy & Airways Patient Platform (GAAPP)
She is a leader among a growing number of advocates calling for action worldwide to improve diagnosis and management that could have a significant effect on patients’ quality of life. Equally critical, advocates say, is the need for global policymakers and governments to recognise COPD as an urgent public health issue that also has far-reaching economic consequences.7
Patients with uncontrolled COPD, which encompasses emphysema and chronic bronchitis,1 may face economic burden including recurring hospital stays and medical bills, need for round-the-clock care and early retirement.2, 8–10 Between 2020 and 2050, COPD is expected to cost the world economy US$4.3trn (at constant 2017 prices), according to one economic model of the impact of COPD in 204 countries and territories.7
“There’s still a long way to go to get people accurately diagnosed and optimised on treatment,” says Ms Winders. “COPD is one of the most frequently hospitalised conditions and most costly. The actual economic spend is outrageous.”7,11
Ms Winders has witnessed the daily burden of living with COPD; both of her parents and a close friend suffer from the condition. Within a decade, she watched her friend go from working as an interior designer and having a vibrant social life to becoming housebound and dependent on oxygen as the disease worsened. “She can no longer go grocery shopping and has to have everything delivered,” she says. “COPD can shrink people’s lives.”
COPD stigma delays diagnosis and hinders care
Why are so many people suffering when screening tools and treatments are available? To answer this question—and identify ways in which public health policies can improve access to care—it’s important to understand some of the unique challenges of COPD, says pulmonologist Gerard J. Criner, MD, FACP, FACCP, director of the Temple Lung Center in Philadelphia and member of the Global Initiative for Chronic Obstructive Lung Disease (GOLD).
For starters, COPD awareness is lacking. In fact, 45% of the public could not correctly identify COPD as a lung disease despite the fact that it kills more people yearly than lung and breast cancer combined.12
COPD also has an image problem. It has long been thought of as primarily a “smoker’s disease,” even though recent studies show that around 30% of patients diagnosed have never smoked.13 For this reason, people may be likely to dismiss respiratory symptoms of COPD, such as breathlessness or coughing up mucus, as everyday congestion or the effects of a cold.1

According to Ms Winders, that stereotype delayed her mother’s COPD care. “By the time we got my mom officially diagnosed with COPD, she could hardly walk to the mailbox,” she says. “I kept telling her, ‘I think you have COPD,’ but she said, ‘I can’t have that, COPD is a smoker's disease.’”
Additionally, patients who are smokers or who have a history of smoking may be deterred from seeking medical attention because they fear they will be judged or that their symptoms will not be taken seriously.14,15 “There’s still a stigma that this is something you did to yourself, and it’s associated with shame and guilt,” Ms Winders adds.
Dr Criner points out that those who do seek help often face hurdles. Many patients who have respiratory symptoms do not receive testing with spirometer instruments that measure air flow, which can delay referrals to specialists who could diagnose and treat them before the situation becomes an emergency.2,16 Many patients also lack access to nearby specialists or care centres.2
The confluence of these factors demonstrates that COPD is more of a public health problem than most realise. One 2018 review of population studies in North and South America, Europe, Australia and Asia estimated that 70% of COPD cases worldwide may be underdiagnosed.17
New understandings and an evolving treatment landscape
A growing understanding of the disease means that the healthcare sector needs to stay on top of new disease management approaches. Treatment options used to consist of mainly inhalers or steroids to widen the airways or suppress inflammation more broadly, but these did not address underlying drivers of the chronic inflammation that is now understood to play an important role in COPD.18, 19

Researchers have learned that COPD is actually a spectrum of disease with different characteristics and types of inflammation promoting COPD progression.3 “Not every COPD patient is the same,” says Dr Criner.
As more tailored options become available, it is important to prioritise appropriate and early diagnosis, allowing for intervention with the appropriate treatment to help slow the progressive nature of the disease. Earlier intervention may also help to alleviate more severe complications from COPD, including frequent flare-ups (or exacerbations), hospitalisations, potentially irreversible lung function loss and cardiovascular complications.2,20-22 This underscores the need for increased public health attention.
These exacerbations can have grave implications for patients, but you don’t see that sense of urgency in the medical or policy community."
Gerard J. Criner, MD, FACP, FACCP, director of the Temple Lung Center in Philadelphia and member of the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
“These exacerbations can have grave implications for patients, but you don’t see that sense of urgency in the medical or policy community,” explains Dr Criner. “There are steps we can take to prioritise intervention, improve patient outcomes and reduce the burden on our healthcare system. It’s time we take this more seriously.”
The cost of staying stagnant
In addition to the health implications of not taking action, there is a significant economic cost. The most obvious is the strain on the healthcare system caused by the vicious cycle of COPD.2 As the disease progresses, patients are at higher risk of exacerbations and experience lung function decline.23 With every exacerbation, patients face an even higher risk of subsequent flare-ups. Flare-ups not only lead to expensive hospitalisations but also repeat stays. One study found 20% of COPD hospitalisations result in readmission within 30 days.22, 24, 25
There is also a connection between COPD and other high-risk conditions like cardiovascular disease. For patients who are experiencing severe exacerbations, the risk of a cardiovascular event can be 14 times higher than those without exacerbations for the following two weeks.2, 26
The direct economic costs of these disease impacts are substantial. According to the COPD Index – which evaluates 34 countries’ approaches to COPD across a range of parameters – the disease accounts for 56% (€38.6bn) of the costs associated with respiratory conditions in the European Union.12 Another study estimated the costs at US$31.3bn in the United States for 2019, with a forecast rise to US$60.5bn in 2029.25 And in China, they are expected to amount to US$3.1trn between 2020 and 2039.27
These costs exclude the hard-to-measure toll on patients’ lives and careers, owing to premature death, physical limitations and missed work days.2, 28, 29 This impact is not limited to the most severe cases. COPD patients are more likely to retire several years early. COPD affects work ability and work productivity leading to reduced work hours, absenteeism and presenteeism.29

The need to act now
As Dr Criner emphasises, the key to better outcomes is early diagnosis and access to different treatments.
And this is achievable by driving policy changes that support prevention, early intervention and reduction of hospitalisations through access to innovative therapies via the appropriate allocation of healthcare budgets.
There are steps we can take to prioritise intervention, improve patient outcomes and reduce the burden on our healthcare system. It’s time we take this more seriously."
Gerard J. Criner, MD, FACP, FACCP, director of the Temple Lung Center in Philadelphia and member of the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
“It takes all of us to make a difference for people with COPD,” says Ms Winders. “And now is the time for policymakers and decision-makers to take action.”
Policy reform is critical to reduce the avoidable human, societal and economic costs of respiratory diseases. There is an urgent need for integrated, data-driven policies and a new care model that addresses chronic respiratory conditions. Progress starts by clearing the air on the misconceptions of the burden of COPD and ensuring the disease is a priority on every country’s public policy agenda.
US.PUL.25.07.0014 | September 2025
References
- 1.World Health Organization, “Chronic obstructive pulmonary disease (COPD),” 6 November 2024.
- 2.“2025 Gold Report - Global Initiative for Chronic Obstructive Lung Disease.” GOLD, 17 Dec. 2024, goldcopd.org/2025-gold-report/.
- 3.Garudadri, Suresh, and Prescott G Woodruff. “Targeting Chronic Obstructive Pulmonary Disease Phenotypes, Endotypes, and Biomarkers.” Annals of the American Thoracic Society vol. 15, Suppl 4 (2018): S234-S238. doi:10.1513/AnnalsATS.201808-533MG
- 4.Ho, Terence et al. “Under- and over-diagnosis of COPD: a global perspective.” Breathe (Sheffield, England) vol. 15,1 (2019): 24-35. doi:10.1183/2073
- 5.National Institute of Health, “Diagnosing and treating COPD: understanding the challenges and finding solutions” 28 October 2011
- 6.“COPD.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, www.cdc.gov/cdi/indicator-definitions/chronic-obstructive-pulmonary-disease.html.
- 7.The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling study. Chen, Simiao et al. The Lancet Global Health, Volume 11, Issue 8, e1183 - e1193
- 8.Minov, Jordan. (2024). Work Ability in Patients with COPD: Premature Retirement Summary. 10.46998/IJCMCR.2024.42.001028.
- 9.Choudhuri, Anirban Hom. “Palliative Care for Patients with Chronic Obstructive Pulmonary Disease: Current Perspectives.” Indian Journal of Palliative Care, U.S. National Library of Medicine, Jan. 2012, pmc.ncbi.nlm.nih.gov/articles/PMC3401737/.
- 10.Bakthavatsalu, Barathi, et al. “The Experience of Hospitalization in People with Advanced Chronic Obstructive Pulmonary Disease: A Qualitative, Phenomenological Study.” Chronic Illness, U.S. National Library of Medicine, June 2023, pmc.ncbi.nlm.nih.gov/articles/PMC9999271/.
- 11.May, Sara M, and James T C Li. “Burden of chronic obstructive pulmonary disease: healthcare costs and beyond.” Allergy and asthma proceedings vol. 36,1 (2015): 4-10. doi:10.2500/aap.2015.36.3812
- 12.“COPD Index.” COPD Index, Copenhagen Institute for Future Studies, respiratoryhealth.org/copd.
- 13.Respiratory Medicine, “Clinical characteristics of chronic obstructive pulmonary disease in never-smokers: A systematic review,” August 2023.
- 14.Lindgren, Sari et al. “Living in negotiation: patients' experiences of being in the diagnostic process of COPD.” International journal of chronic obstructive pulmonary disease vol. 9 441-51. 6 May. 2014, doi:10.2147/COPD.S60182 https://pmc.ncbi.nlm.nih.gov/articles/PMC4018318/#sec19
- 15.Stigma: An Unmet Public Health Priority in COPD - the Lancet Respiratory Medicine, The Lancet Respiratory Medicine, Sept. 2021, www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00316-7/fulltext.
- 16.Johns, David P, et al. “Diagnosis and Early Detection of COPD Using Spirometry.” Journal of Thoracic Disease, U.S. National Library of Medicine, Nov. 2014.
- 17.Underdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease | American Journal of Respiratory and Critical Care Medicine, American Journal of Respiratory and Critical Care Medicine, 12 Apr. 2018, www.atsjournals.org/doi/10.1164/rccm.201804-0621CI.
- 18.Vogelmeier, Claus F, et al. Goals of COPD Treatment: Focus on Symptoms and Exacerbations, U.S. National Library of Medicine, 21 Mar. 2020, pubmed.ncbi.nlm.nih.gov/32250871/.
- 19.Cazzola, Mario et al. “Novel Anti-Inflammatory Approaches to COPD.” International journal of chronic obstructive pulmonary disease vol. 18 1333-1352. 29 Jun. 2023, doi:10.2147/COPD.S419056
- 20.Sun Y, Zhou J. New insights into early intervention of chronic obstructive pulmonary disease with mild airflow limitation. Int J Chron Obstruct Pulmon Dis. 2019 May 23;14:1119-1125. doi: 10.2147/COPD.S205382. PMID: 31213792; PMCID: PMC6536809.
- 21.Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax 2011; 66(7): 585-90 https://pubmed.ncbi.nlm.nih.gov/21515553.
- 22.Suissa, S., Dell'Aniello, S. & Ernst, P., “Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality,” Thorax, Vol. 67(11), pp. 957-963, November 2012. doi: 10.1136/thoraxjnl-2011-201518. Epub: 8 June 2012. PMID: 22684094; PMCID: PMC3505864.
- 23.Barnes, P. J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 138(1), 2016, 16-27
- 24.Gershon, A.S., Thiruchelvam, D., Aaron, S., Stanbrook, M., Vozoris, N., Tan, W.C, Cho, E. & To, T., “Socioeconomic status (SES) and 30-day hospital readmissions for chronic obstructive pulmonary (COPD) disease: A population-based cohort study,” PLoS ONE, 14(5): e0216741, 21 May 2019. https://doi.org/10.1371/journal.pone.0216741
- 25.Mannino, David M et al. “National and Local Direct Medical Cost Burden of COPD in the United States From 2016 to 2019 and Projections Through 2029.” Chest vol. 165,5 (2024): 1093-1106. doi:10.1016/j.chest.2023.11.040
- 26.American Journal of Respiratory and Critical Care Medicine, “Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study,” 1 July 2023.
- 27.Park, J-E., et al. “Modeling the Health and Economic Burden of Chronic Obstructive Pulmonary Disease in China From 2020 to 2039: A Simulation Study.” Value in Health Regional Issues, vol. 32, Nov. 2022, pp. 8–16. https://doi.org/10.1016/j.vhri.2022.06.002.
- 28.van Helvoort, Hanneke Ac et al. “Respiratory constraints during activities in daily life and the impact on health status in patients with early-stage COPD: a cross-sectional study.” NPJ primary care respiratory medicine vol. 26 16054. 13 Oct. 2016, doi:10.1038/npjpcrm.2016.54
- 29.de Sousa Sena, Riany et al. “Work productivity loss in mild to moderate COPD: lessons learned from the CanCOLD study.” The European respiratory journal vol. 50,3 1701154. 12 Sep. 2017, doi:10.1183/13993003.01154-2017
